clinical trial · NCT07576699
CK0802 for Treatment of Steroid Refractory Graft vs. Host Disease (GVHD)
Cellenkos, Inc.·phase2·not yet recruiting·n = 12
Steroid Refractory Graft Versus Host DiseaseCK0802 (Allogeneic, Cryopreserved, Cord blood-derived T-regulatory cells, cells that are not HLA matched)
brief summary
The purpose of this study is to determine the efficacy and safety of CK0802 Tregs for treatment of refractory GVHD (graft-versus-host disease)
started
Jul 1, 2026
primary completion
Jun 30, 2028
completion
Jun 30, 2029
last updated
May 8, 2026
detailed description
This clinical trial will be conducted in two parts where the first part of Phase 1b will determine the safety and tolerability of CK0802 in patients with steroid refractory GVHD and the second part of Phase 2a will examine the preliminary efficacy of CK0802 in patients with steroid refractory GVHD
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol